Tumor-infiltrating lymphocytes, low PD1/PD-L1 expression, and the presence of neo-antigens are likely associated with higher rates of response, but only provide a glimpse of the complex system that precludes response to immunotherapy [25]. The gene discussed is PDCD1; the disease is neoplasm.